Young glial progenitor cells competitively replace aged and diseased human glia in the adult chimeric mouse brain.
Ricardo VieiraJohn N MarianiNguyen P T HuynhHans Jacob Teglbjærg StephensenRenee SollyAshley TateSteven SchanzNatasha CotrupiMarzieh MousaeiJon SporringAbdellatif BenraissSteven A GoldmanPublished in: Nature biotechnology (2023)
Competition among adult brain cells has not been extensively researched. To investigate whether healthy glia can outcompete diseased human glia in the adult forebrain, we engrafted wild-type (WT) human glial progenitor cells (hGPCs) produced from human embryonic stem cells into the striata of adult mice that had been neonatally chimerized with mutant Huntingtin (mHTT)-expressing hGPCs. The WT hGPCs outcompeted and ultimately eliminated their human Huntington's disease (HD) counterparts, repopulating the host striata with healthy glia. Single-cell RNA sequencing revealed that WT hGPCs acquired a YAP1/MYC/E2F-defined dominant competitor phenotype upon interaction with the host HD glia. WT hGPCs also outcompeted older resident isogenic WT cells that had been transplanted neonatally, suggesting that competitive success depended primarily on the relative ages of competing populations, rather than on the presence of mHTT. These data indicate that aged and diseased human glia may be broadly replaced in adult brain by younger healthy hGPCs, suggesting a therapeutic strategy for the replacement of aged and diseased human glia.
Keyphrases
- subarachnoid hemorrhage
- endothelial cells
- single cell
- type diabetes
- wild type
- metabolic syndrome
- embryonic stem cells
- mesenchymal stem cells
- machine learning
- multidrug resistant
- cell cycle arrest
- patient safety
- high throughput
- big data
- bone marrow
- deep learning
- quality improvement
- signaling pathway
- insulin resistance
- cell therapy